VENUSREM

Venus Remedies Share Price

₹310.20 -1.95 (-0.62%)

22 Feb, 2025 21:32

SIP TrendupStart SIP in VENUSREM

Start SIP

Performance

  • Low
  • ₹310
  • High
  • ₹318
  • 52 Week Low
  • ₹270
  • 52 Week High
  • ₹428
  • Open Price₹317
  • Previous Close₹312
  • Volume14,664

Investment Returns

  • Over 1 Month + 3.01%
  • Over 3 Month + 3.87%
  • Over 6 Month -9.68%
  • Over 1 Year -17.05%
SIP Lightning

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 11.9
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 415
  • P/B Ratio
  • 0.8
  • Average True Range
  • 16.79
  • EPS
  • 20.85
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.56
  • RSI
  • 48.78
  • MFI
  • 80.37

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹310.20
-1.95 (-0.62%)
pointer
  • stock-down_img
  • Bearish Moving Average 13
  • stock-up_img
  • Bullish Moving Average 3
  • 20 Day
  • ₹313.54
  • 50 Day
  • ₹312.48
  • 100 Day
  • ₹318.19
  • 200 Day
  • ₹324.15

Resistance and Support

312.75 Pivot Speed
  • R3 323.55
  • R2 320.80
  • R1 315.50
  • S1 307.45
  • S2 304.70
  • S3 299.40

What's your outlook on Venus Remedies?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 648.08 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 7% is okay, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at C which is evident from recent supply seen, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-04 Quarterly Results
2024-10-29 Quarterly Results
2024-08-13 Quarterly Results & A.G.M.
2024-05-30 Audited Results
2024-02-14 Quarterly Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
1.11%
45.42%
11.71%

About Venus Remedies

  • NSE Symbol
  • VENUSREM
  • BSE Symbol
  • 526953
  • Chairman & Managing Director
  • Mr. Pawan Chaudhary
  • ISIN
  • INE411B01019

Similar Stocks to Venus Remedies

Venus Remedies FAQs

Venus Remedies share price is ₹310 As on 22 February, 2025 | 21:18

The Market Cap of Venus Remedies is ₹414.6 Cr As on 22 February, 2025 | 21:18

The P/E ratio of Venus Remedies is 11.9 As on 22 February, 2025 | 21:18

The PB ratio of Venus Remedies is 0.8 As on 22 February, 2025 | 21:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23